MindBio Therapeutics Corp (CSE:MBIO; Frankfurt:WF6) started pre-screening for participant entry into Phase 2 LSD-microdosing clinical trials. The clinical trials are a world first with approvals for take home use of...
Close-held Neurogene and Neoleukin Therapeutics (NASDAQ:NLTX) entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Neurogene’s...
A Phase 1 trial of Anixa Biosciences’ (NASDAQ:ANIX) breast cancer vaccine and women survivors were featured in an article on the website of England’s Daily Mail newspaper. Anixa’s CEO, Amit Kumar, Ph.D., described the...
Ondine Biomedical (LON:OBI) was awarded the TAYYABA HASAN IMPACT AWARD at the 18th World Congress of International Photodynamic Association (IPA) in Finland for demonstrating “exceptional perseverance and clinical...
Athira Pharma (NASDAQ:ATHA) is presenting new data supporting its pipeline of small molecule therapeutic candidates designed to enhance the HGF/MET neurotrophic system at the Alzheimer’s Association International...
First Wave BioPharma’s (NASDAQ:FWBI) is unlikely to achieve the primary endpoint based on preliminary results from the Phase 2 SPAN study for the treatment of exocrine pancreatic insufficiency in patients with cystic...
The FDA completed a review of Tryp Therapeutics’ (CSE:TRYP; OTCQB:TRYPF) investigational new drug application, permitting the company to proceed with a Phase 2a clinical trial at Massachusetts General Hospital (MGH)...
With sales falling short of expectations, Theratechnologies (TSX:TH; NASDAQ:THTX) is reducing its R&D head count. Second quarter revenue fell 8.9% to $17.5-million (U.S.) from $19.3-million a year ago. “Second...
The FDA granted fast track designation to Synlogic’s (NASDAQ:SYBX) labafenogene marselecobac (previously known as SYNB1934) for the treatment of phenylketonuria (PKU). Labafenogene marselecobac also has received rare...
The Canadian Intellectual Property Office issued a patent covering Anixa Biosciences’ (NASDAQ:ANIX) novel chimeric antigen receptor T-cell (CAR-T) cancer treatment technology, which has been licensed from The Wistar...